Literature DB >> 11422332

Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy.

E Wirrell1, C Camfield, P Camfield, J Dooley.   

Abstract

PURPOSE: In children with childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE), to determine the impact of failure of initial antiepileptic drug (AED) for lack of efficacy in eventual seizure control and long-term remission of epilepsy.
METHODS: Centralized EEG records for the province of Nova Scotia allowed identification of all children seen with CAE or JAE between 1977 and 1985. Information regarding success or failure of initial AED in fully controlling seizures and long-term seizure control and remission of epilepsy was collected by patient questionnaire and chart review.
RESULTS: Eighty-six of 92 eligible patients were followed up (75 CAE, 11 JAE). Initial AED treatment was successful in 52 (60%) of 86. Success tended to be greater for valproate (VPA) than for other AEDs (p = 0.07), and lower if generalized tonic-clonic or myoclonic seizures coexisted (p < 0.004 and p < 0.03). Terminal remission was more likely if the initial AED was successful than if it had failed (69% vs. 41%; p < 0.02). Compared with those in whom the initial AED was successful, subjects whose initial AED had failed were more likely to progress to juvenile myoclonic epilepsy (JME) at last follow-up (32% vs. 10%; p < 0.02) and to develop intractable epilepsy (17% vs. 2%; p < 0.04).
CONCLUSIONS: Initial AED was successful in 60% of children with AE. If the first AED failed, the outcome was less favorable, with a lower rate of terminal remission and a higher rate of progression to JME and intractable epilepsy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422332     DOI: 10.1046/j.1528-1157.2001.02401.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  The developmental evolution of the seizure phenotype and cortical inhibition in mouse models of juvenile myoclonic epilepsy.

Authors:  Fazal Arain; Chengwen Zhou; Li Ding; Sahar Zaidi; Martin J Gallagher
Journal:  Neurobiol Dis       Date:  2015-06-06       Impact factor: 5.996

2.  Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.

Authors:  Tracy A Glauser; Avital Cnaan; Shlomo Shinnar; Deborah G Hirtz; Dennis Dlugos; David Masur; Peggy O Clark; Peter C Adamson
Journal:  Epilepsia       Date:  2012-11-21       Impact factor: 5.864

3.  Long-term prognosis for childhood and juvenile absence epilepsy.

Authors:  Eugen Trinka; Sarah Baumgartner; Iris Unterberger; Josef Unterrainer; Gerhard Luef; Edda Haberlandt; Gerhard Bauer
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

4.  Valproate in children with newly diagnosed idiopathic generalized epilepsy.

Authors:  K D Holland; S Monahan; D Morita; G Vartzelis; T A Glauser
Journal:  Acta Neurol Scand       Date:  2010-01-06       Impact factor: 3.209

5.  The current state of absence epilepsy: can we have your attention?

Authors:  Jeffrey R Tenney; Tracy A Glauser
Journal:  Epilepsy Curr       Date:  2013-05       Impact factor: 7.500

6.  Absence Epilepsy: Older vs Newer AEDs.

Authors:  Jeffrey R Tenney; Sejal V Jain
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

Review 7.  A Practical Guide to Treatment of Childhood Absence Epilepsy.

Authors:  Sudha Kilaru Kessler; Emily McGinnis
Journal:  Paediatr Drugs       Date:  2019-02       Impact factor: 3.022

8.  Difficult to treat absence seizures in children: A single-center retrospective study.

Authors:  Samo Gregorčič; Jaka Hrovat; Neli Bizjak; Zvonka Rener Primec; Tadeja Hostnik; Blaž Stres; Mirjana Perković Benedik; Damjan Osredkar
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086

Review 9.  Patient considerations in the management of focal seizures in children and adolescents.

Authors:  Daniel Kenney; Elaine Wirrell
Journal:  Adolesc Health Med Ther       Date:  2014-04-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.